ANTI-NEPRILYSIN MARKET ANALYSIS

Anti-Neprilysin MarketSize and Trends

The global anti neprilysin market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% during the forecast period (2023-2030).

Figure 1. Global Anti-Neprilysin Market Share (%),By Drug Type, 2023

Figure 2. Global Anti-Neprilysin Market Share (%), By Region, 2023

Market- Trends

Increasing Research and Development Activities Regarding Anti-Neprilysin drugs

Growing research and development activities around the world is a major factor that boosts demand for anti-neprilysin drugs. For instance, PubMed, a free search engine for biological databases, published a research studies in September 2020, about a randomized, double-blind, placebo-controlled, single ascending dose (50–600 mg TD-0714) and multiple ascending dose (10–200 mg TD-0714 q.d. for 14 days) trial of TD-0714, an orally active, potent, and selective inhibitor of human neprilysin (NEP) in development for the treatment of chronic heart failure. The study was conducted on healthy volunteers. It was concluded that TD-0714 was generally well tolerated, and no serious adverse events or clinically significant effects on vital signs or electrocardiogram parameters were observed. The drug exhibited dose-proportional pharmacokinetics (PKs) with high oral bioavailability, minimal accumulation after once-daily dosing, and negligible renal elimination.

Introduction of New Anti-Neprilysin Drugs Products

Increasing product launches by key market players can drive growth of the global anti-neprilysin market. For instance, on January 21, 2023, MSN Laboratories, a a India-based research-based,  integrated pharmaceutical company, announced the relaunch of Sacubitril/Valsartan tablets, 50 mg, 100 mg, and 200 mg, for heart failure with reduced ejection fraction (HFrEF) under the brand name Sacutan, at lower prices.